Full Press Release Details
dupixent dupilumab approved by european commission as the first and only targeted medicine indicated for eosinophilic esophagitis.
REGN
dupixent dupilumab approved by european commission as the first and only targeted medicine indicated for eosinophilic esophagitis
Key Takeaway: dupixent dupilumab approved by european commission as the first and only targeted medicine indicated for eosinophilic esophagitis